The pneumococcus bacterium (Streptococcus pneumoniae) kills close to half a million children younger than five years of age each year, mainly in low-resource settings. It is the leading cause of childhood pneumonia, which is the number one killer of children under five worldwide, and a cause of meningitis (inflammation of the covering of the brain), ear infections, and bacteremia (blood stream infection). Pneumococcal disease can be treated with antibiotics; however, antibiotic-resistant strains are becoming more common worldwide. Current pneumococcal vaccines approved for use in children are effective against strains common in the industrialized world and some low-resource countries, but do not cover all 90+ pneumococcal serotypes and they are complex and expensive to manufacture. Several additional vaccines are in development.
On the PATH website
- Developing new pneumococcal vaccines tailored for children that need them most.
- The pneumococcus bacterium (Streptococcus pneumoniae) is responsible for nearly half a million deaths of children less than five years old each year according to the World Health Organization. It can cause pneumonia, meningitis (inflammation of the covering of the brain), otitis media (inner ear infections), and bacteremia (blood stream infection). Children less than two years old are especially vulnerable to infection and the vast majority of pneumococcal pneumonia deaths in children occur in low-income settings.
- The bacteria normally are carried in the nose or upper throat and are spread through sneezing, coughing, or being in close proximity with an infected person. Up to ninety percent of children carry the bacteria without showing any signs or symptoms, but they can still infect others.
- Drugs such as penicillin are generally effective for treating pneumococcal infections, but antibiotic-resistant pneumococcus is becoming more common worldwide. This situation makes prevention of the disease through the widespread use of pneumococcal vaccines and other interventions (like exclusive breastfeeding, handwashing, good nutrition, and clean household air) even more important.
- Oxygen therapy is another important treatment for hypoxia (oxygen deficiency), a potentially fatal condition that can result from pneumococcal pneumonia.
- GlaxoSmithKline Biological’s Synflorix™ and Pfizer’s Prevnar 13® are two pediatric pneumococcal conjugate vaccines (PCVs) on the market and offer broader protection against 10 and 13 serotypes, respectively. Prevnar 13® is also approved for use in adults 18 to 49 years of age.
- Pneumococcal polysaccharide vaccines by Merck and Sanofi Pasteur protect against 23 pneumococcal serotypes, but are recommended mainly for use in adults.
- Many other vaccine candidates are also in the development pipeline, including candidates designed to be more affordable and to provide broad protection across the full spectrum of pneumococcal serotypes.
- Current pneumococcal vaccines, even with added strain coverage, do not protect against all 90+ pneumococcal serotypes and they are complex and relatively expensive to manufacture.
There are several key causes of childhood pneumonia and meningitis (inflammation of the covering of the brain), including pneumococcus and meningococcus bacteria. Learn more about meningococcus.
In addition, there are a number of bacterial and viral causes of respiratory diseases, all of which can affect the lungs and upper airways, including pneumococcus, respiratory syncytial virus (RSV), and influenza. Learn more about RSV. Learn more about influenza.
- United Nations Children’s Fund. One Is Too Many: Ending Child Deaths From Pneumonia and Diarrhoea.
- US Centers for Disease Control and Prevention. Pneumococcal Vaccination.
- World Health Organization. Estimated Hib and Pneumococcal Deaths for Children Under 5 Years of Age, 2008.
Page last updated: July 2017.
Photo: PATH/Ashley Latimer.